PMID- 34455227
OWN - NLM
STAT- MEDLINE
DCOM- 20211227
LR  - 20220531
IS  - 1532-3080 (Electronic)
IS  - 0960-9776 (Print)
IS  - 0960-9776 (Linking)
VI  - 60
DP  - 2021 Dec
TI  - Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced 
      breast cancer: A meta-analysis and systematic review.
PG  - 26-34
LID - S0960-9776(21)00439-2 [pii]
LID - 10.1016/j.breast.2021.08.009 [doi]
AB  - OBJECTIVE: This meta-analysis aimed to investigate the efficacy and safety of 
      poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors in BRCA-mutated 
      advanced breast cancer patients comprehensively. METHODS: We conducted a 
      systematic literature research through PubMed, the Cochrane Central Register of 
      Controlled Trials (CENTRAL), Embase, China National Knowledge Infrastructure 
      (CNKI), wanfang, China Biology Medicine disc (CBMdisc), and ClinicalTrials.gov 
      from inception to January 2021. Randomized controlled trials (RCTs) with 
      available data comparing PARP inhibitors versus control therapy in BRCA-mutated 
      advanced breast cancer were eligible for analysis. Statistical analyses were 
      performed with Review Manager (RevMan) version 5.4 and R version 4.0.3. RESULTS: 
      1706 studies were retrieved in total, and 4 RCTs with 1540 patients were eligible 
      for meta-analysis finally. The results showed that progression-free survival 
      (PFS) and overall survival (OS) were significantly improved in germline 
      BRCA-mutated breast cancer patients with PARP inhibitors (HR 0.64, 95% CI 
      [0.56-0.74]; HR 0.86, 95% CI [0.74-0.99], respectively) with no significant 
      heterogeneity across studies (I(2) = 22%, chi(2) p = 0.28; I(2) = 0%, chi(2) 
      p = 0.70, respectively). There was no significant difference in the overall 
      adverse events (AEs), grade>/=3 AEs and AEs leading to treatment discontinuation 
      between PARP inhibitor arms and control arms (RR 1.01, 95% CI [0.99-1.02]; RR 
      0.95, 95% CI [0.83-1.09]; RR 1.17, 95% CI [0.87-1.57], respectively). Based on 
      the available data, PARP inhibitors provided comparable or better results than 
      control arms in improving the quality of life in BRCA-mutated advanced breast 
      cancer patients. CONCLUSIONS: PARP inhibitors prolonged PFS and OS among patients 
      with BRCA-mutated advanced breast cancer with tolerable safety and improved 
      quality of life.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Sun, Ximu
AU  - Sun X
AD  - Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital 
      Medical University, No.17, Qi He Lou Street, Dongcheng District, Beijing, 100026, 
      China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 8 
      Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 8 
      Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China.
FAU - Zhao, Zhixia
AU  - Zhao Z
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 8 
      Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China.
FAU - Feng, Xin
AU  - Feng X
AD  - Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital 
      Medical University, No.17, Qi He Lou Street, Dongcheng District, Beijing, 100026, 
      China. Electronic address: fengxin1115@ccmu.edu.cn.
FAU - Liu, Lihong
AU  - Liu L
AD  - Department of Pharmacy, China-Japan Friendship Hospital, No.2 Yinghuayuan 
      Dongjie, Chaoyang District, Beijing, 100029, China. Electronic address: 
      liulihong@bjcyh.com.
FAU - Ma, Zhuo
AU  - Ma Z
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 8 
      Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China. Electronic 
      address: mazhuo2013@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210821
PL  - Netherlands
TA  - Breast
JT  - Breast (Edinburgh, Scotland)
JID - 9213011
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
SB  - IM
MH  - *Antineoplastic Agents/therapeutic use
MH  - *Breast Neoplasms/drug therapy/genetics
MH  - Female
MH  - Humans
MH  - Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
MH  - Poly(ADP-ribose) Polymerases/therapeutic use
MH  - Progression-Free Survival
PMC - PMC8399371
OTO - NOTNLM
OT  - BRCA mutation
OT  - Breast cancer
OT  - Poly(ADP-ribose) polymerase inhibitors
OT  - Triple-negative breast cancer
COIS- Declaration of competing interest All authors declare that they have no conflict 
      of interest.
EDAT- 2021/08/30 06:00
MHDA- 2021/12/28 06:00
PMCR- 2021/08/21
CRDT- 2021/08/29 20:54
PHST- 2021/04/12 00:00 [received]
PHST- 2021/07/29 00:00 [revised]
PHST- 2021/08/16 00:00 [accepted]
PHST- 2021/08/30 06:00 [pubmed]
PHST- 2021/12/28 06:00 [medline]
PHST- 2021/08/29 20:54 [entrez]
PHST- 2021/08/21 00:00 [pmc-release]
AID - S0960-9776(21)00439-2 [pii]
AID - 10.1016/j.breast.2021.08.009 [doi]
PST - ppublish
SO  - Breast. 2021 Dec;60:26-34. doi: 10.1016/j.breast.2021.08.009. Epub 2021 Aug 21.